23andMe Holding Shares Outstanding 2021-2024 | MEHCQ
23andMe Holding shares outstanding from 2021 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
23andMe Holding Annual Shares Outstanding
(Millions of Shares) |
| 2024 |
24 |
| 2023 |
23 |
| 2022 |
18 |
| 2021 |
5 |
| 2020 |
1 |
| 2020 |
4 |
23andMe Holding Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-12-31 |
26 |
| 2024-09-30 |
26 |
| 2024-06-30 |
25 |
| 2024-03-31 |
24 |
| 2023-12-31 |
24 |
| 2023-09-30 |
24 |
| 2023-06-30 |
23 |
| 2023-03-31 |
23 |
| 2022-12-31 |
23 |
| 2022-09-30 |
22 |
| 2022-06-30 |
22 |
| 2022-03-31 |
18 |
| 2021-12-31 |
21 |
| 2021-09-30 |
20 |
| 2021-06-30 |
8 |
| 2021-03-31 |
1 |
| 2020-12-31 |
5 |
| 2020-09-30 |
5 |
| 2020-06-30 |
5 |
| 2020-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.220B |
|
23andMe Inc. is a consumer genetics and research company. It involved in discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory and cardiovascular diseases, in addition to other therapeutic areas. 23andMe Inc., formerly known as VG Acquisition Corp., is headquartered in Sunnyvale, CA.
|
